Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer.
about
Adenoviral vector immunity: its implications and circumvention strategies.Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity.Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectinsEngineering biomaterial systems to enhance viral vector gene delivery.The targeted transduction of MMP-overexpressing tumor cells by ACPP-HPMA copolymer-coated adenovirus conjugatesChoindroitinase ABC I-mediated enhancement of oncolytic virus spread and anti tumor efficacy: a mathematical model.pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesisEnhancing the therapeutic efficacy of adenovirus in combination with biomaterials.Perspectives in vector development for systemic cancer gene therapy.Anti-tumor effect of adenovirus-mediated gene transfer of pigment epithelium-derived factor on mouse B16-F10 melanomaOncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time.Strategies to overcome host immunity to adenovirus vectors in vaccine development.Advances with the use of bio-inspired vectors towards creation of artificial viruses.Retargeting of viruses to generate oncolytic agents.The evolution of adenoviral vectors through genetic and chemical surface modifications.Tropism-modification strategies for targeted gene delivery using adenoviral vectors.Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis on poxviruses.EGFR-Targeted Adenovirus Dendrimer Coating for Improved Systemic Delivery of the Theranostic NIS GeneChemical conjugation of cowpea mosaic viruses with reactive HPMA-based polymers.Beyond Gene Delivery: Strategies to Engineer the Surfaces of Viral Vectors.
P2860
Q33565630-CA82EDCB-F1B3-445E-A2FF-F23BC79FEAA4Q34069571-366DE0FF-0B90-4D83-8EC4-CC6DE3017FF1Q34765825-3E3B05E3-0326-42E3-8F8C-31AAA56121BAQ35144415-60856AAC-8FC1-47A7-98CE-B50B24005596Q35202335-AF3FA903-3B2D-48F7-B8C2-89488B7C47AEQ35210355-1413FF09-FA17-473C-8E19-EE12EBDF2393Q35569909-A0F47EE7-61DC-4A1D-AF0B-3988C4EFCA93Q35624010-38D5DBDC-AA96-4342-ACE7-BCACDDF6FD4AQ37214820-E26709F4-AB4F-4EDF-8754-E88275953AC4Q37238522-EC3A99E1-8338-4AD4-8B99-D43BD96C6D2BQ37448942-2BBD6CE3-98B0-434F-93C3-FBD7A9A35F8FQ37503253-1ED83AD7-B2DC-469D-83A7-D979C0F5EC2BQ37691446-72DE9D0D-39B8-43CF-B805-EE6D174B373CQ37982062-F9E20D85-C93A-4438-B655-30C405B246DEQ38189250-5B63102D-E1A9-4E52-B146-DFE1E68D60F5Q38614156-E7CDD1F0-6843-400F-A6C6-CC039D61AB03Q38924539-8358EF71-60FD-4B26-A872-E95261013998Q41866984-26FA2E16-9345-4808-9727-647855700EE6Q43033817-91FA2845-5EC9-45F6-8942-B0DE60F4E7F7Q51857382-8D579692-36AD-4553-9A36-DD1B8A664E8B
P2860
Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Retargeting polymer-coated ade ...... model of human ovarian cancer.
@en
Retargeting polymer-coated ade ...... model of human ovarian cancer.
@nl
type
label
Retargeting polymer-coated ade ...... model of human ovarian cancer.
@en
Retargeting polymer-coated ade ...... model of human ovarian cancer.
@nl
prefLabel
Retargeting polymer-coated ade ...... model of human ovarian cancer.
@en
Retargeting polymer-coated ade ...... model of human ovarian cancer.
@nl
P2093
P50
P356
P1476
Retargeting polymer-coated ade ...... model of human ovarian cancer.
@en
P2093
Joanne Morrison
Karel Ulbrich
Leonard W Seymour
Lois Chandler
Mark Stevenson
Nicola K Green
Sarah Hale
Simon S Briggs
Vivien Mautner
P304
P356
10.1002/JGM.1121
P577
2008-03-01T00:00:00Z